We noticed that patients with T2D had a higher rate of pre-existing hypertension in our study, which may bring concerns of possible effects by ACE2 inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on the prognosis of COVID-19. This evidence concerns the gene ACE2 and COVID-19.